Hanall Biopharma Co., Ltd. (009420.KS) KSC

Currency In KRW

AD

Valuation

Market Cap2.18T
Enterprise Value2.19T
P/E Ratio-117.2
PEG Ratio-0.18
Price/Sales Ratio17.67
Price/Book Ratio18.26
Enterprise/Revenue17.76
Enterprise/EBITDA-213.32

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.15
Operating Margin0.03
AD

Management Effectiveness

Return On Assets-0.1
Return On Equity-0.15

Income Statement

Revenue155.18B
Revenue/Share3,113.64
Gross Profit79.1B
EBITDA1.94B
Net Income-5.56B
Diluted EPS-111.55

Balance Sheet

Total Cash30.2B
Total Cash/Share578.01
Total Debt44.99B
Total Debt/Equity0.28
Current Ratio1.49
Book Value Per Share3,093.85

Price History

52-Week Change98.59
52-Week High73,000
52-Week Low28,950
Moving Average 50 Days54,077
Moving Average 200 Days51,256.25

Statistics

Average Volume518,359
Shares Outstanding50.86M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor10:1
Last Split DateMay 03, 2006
AD